Skip to main content
. 2022 Apr 27;81(8):1136–1142. doi: 10.1136/annrheumdis-2022-222212

Figure 5.

Figure 5

Clinical efficacy treatment comparison (week 24 SRI-4 response rate, iberdomide 0.45 mg—placebo) within prespecified patient subsets defined by gene expression at baseline. Gene module score cut-offs were set as described in figure 5. See online supplemental table 5 for numeric data. IFN, interferon; SLE, systemic lupus erythematosus; SRI-4, SLE Responder Index-4.